852 / 1851
PCV x 4 + RT vs RT alone: RTOG 9402
289 AA or AOA patients
Randomization to receive either 4 PCV (procarbazine, lomustine, vincristine) followed by RT 59.4 Gy/33 fr or RT alone
No differences in term of median OS between the 2 arms
(4.9 vs 4.7 years)
PFS benefit for patients receiving PCV + RT (2.6 vs 1.7 years)
Higher rates of G3-G4 toxicity in patients receiving PCV+RT (65%), with at least 1 fatal event.
1p/19q codeletion is a favorable prognostic factor
(median OS >7 vs 2.8 years)
Cairncross G. et al. JCO 2006;24